Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2004-06-04
2009-10-13
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S571000
Reexamination Certificate
active
07601756
ABSTRACT:
A method for treating irritable bowel syndrome (IBS) is included. The method includes the step of administering a fibric acid derivative to a patient diagnosed with IBS in order to alleviate the symptoms associated with IBS.
REFERENCES:
patent: 3262850 (1966-07-01), Jones et al.
patent: 3674836 (1972-07-01), Creger
patent: 3781328 (1973-12-01), Witte et al.
patent: 3948973 (1976-04-01), Phillips
patent: 4058552 (1977-11-01), Mieville
patent: 4895726 (1990-01-01), Curtet et al.
patent: 6074670 (2000-06-01), Stamm et al.
patent: 6277405 (2001-08-01), Stamm et al.
patent: 6399640 (2002-06-01), Sahoo et al.
patent: 6525083 (2003-02-01), Acton et al.
patent: 6569879 (2003-05-01), Liu et al.
patent: 6589552 (2003-07-01), Stamm et al.
patent: 6652881 (2003-11-01), Stamm et al.
patent: 6713508 (2004-03-01), Sahoo et al.
patent: 2001/0028895 (2001-10-01), Bisgaier et al.
patent: 2002/0013334 (2002-01-01), Robl et al.
patent: 2002/0042441 (2002-04-01), Acton, III et al.
patent: 2002/0055529 (2002-05-01), Bisgaier et al.
patent: 2002/0103242 (2002-08-01), Sahoo et al.
patent: 2002/0173663 (2002-11-01), Liu et al.
patent: 2003/0045553 (2003-03-01), Bussolari et al.
patent: 2003/0092736 (2003-05-01), Cheng et al.
patent: WO 03/059294 (2003-07-01), None
The Merck Index, 17thedition (1999) p. 208.
Camilleri et al.; The Irritable Bowel Syndrome: Mechanisms and a Practical Approach to Management; Annals of Internal Medicine; vol. 116, No. 12 (Part I); Jun. 15, 1992, pp. 1001-1008.
Fruchart et al.; Consensus for the Use of Fibrates in the Treatment of Dyslipoproteinemia and Coronary Heart Disease; The American Journal of Cardiology; vol. 81; Apr. 1, 1998; pp. 912-917.
Adkins et al.; Micronised Fenofibrate; Drugs; vol. 54 (4); Oct. 1997; pp. 615-633.
Fibric Acid Derivatives; http://www.drugdigest.org/DD/Comparison/New Comparison/0,10621,35-15,00.html; (2003 Express Scripts, Inc.) (as printed on Jun. 2, 2003).
Rosenson; Lipid Lowering with Fibric Acid Derivatives; http://www.uptodate.com/patient—info/topicpages/topics/LipidDis/7385.asp?usd=98622024... (as printed on Jun. 2, 2003).
Hoffmann-La Roche Ltd./Ltee; Product Monograph-Bezallip®; Date of Preparation: Mar. 18, 1994; Date of Revision: Jan. 29, 2002; pp. 1-11.
Lopid®; Information for Health Professionals Data Sheet; http://www.medsafe.govt.nz/profs/Datasheet/l/Lopidcaptab.htm; (as printed on Jun. 3, 2003).
Kolata; New Evidence Cites Overactive Nerves for Irritable Bowel; The New York Times Medical Science; Tuesday, Feb. 2, 1988.
Dr. Peter H. Gott, Family Doctor; IBS affects people of all ages; Trenton Times; Jul. 26, 2003.
Drossman et al.; The Irritable Bowel Syndrome: Review and a Graduated Multicomponent Treatment Approach; Annals of Internal Medicine; vol. 116, No. 12 (Part 1); Jun. 15, 1992; pp. 1009-1016.
Almy; Management of the Irritable Bowel Syndrome; Different Views of the Same Disease; Annals of Internal Medicine; vol. 116; No. 12 (Part 1); Jun. 15, 1992; pp. 1027-1028.
Christensen; Pathophysiology of the Irritable bowel syndrome; The Lancet; vol. 340; Dec. 12, 1992; pp. 1444-1447.
Schreiber et al.; Recombinant Erythropoietin for the Treatment of Anemia in Inflammatory Bowel Disease; The New England Journal of Medicine; vol. 334, No. 10; Mar. 7, 1996; pp. 619-682.
Lydiard; Anxiety and the Irritable Bowel Syndrome: Psychiatric, Medical, or Both?; J Clin Psychiatry; vol. 58, (suppl 3); 1997; pp. 51-58.
Wender et al.; Prevalence of Attention Deficit Disorder, Residual Type, and Other Psychiatric Disorders in Patients With Irritable Colon Syndrome; Am J Psychiatry; vol. 140:12; Dec. 1983; pp. 1579-1582.
Hendricks; Bowels in an Uproar; John Hopkins Magazine; Apr. 1997; pp. 20-25.
Press Release; Cypress Bioscience Holds Kick-Off Meeting for New Clinical Study Using Milnacipran to Treat Irritable Bowel Syndrome; Cypress Bioscience, Inc.; San Diego, CA, Jun. 25, 2003.
Press Release: Cypress Bioscience Revises Milnacipran License with Pierre Fabre Medicament to Improve Economic Terms and Expand the Licensed Field; Cypress Bioscience, Inc.; San Diego, CA ; Jun. 9, 2003.
Press Release: Cypress Bioscience, Inc.'s Announces Topline Final Results of Milnacipran Phase II Study in Fibromyalgia Syndrome; Cypress Bioscience, Inc.; San Diego, CA; Feb. 10, 2003.
Fruchart et al.; Consensus for the use of fibrates in the treatment of dyslipoproteinemia and cornory heart disease; Am J Cardiology; vol. 81 (7); Apr. 1, 1998; pp. 912-917 (MEDLINE Abstract).
Weber et al.; Clinical approaches to irritable bowel syndrome; The Lancet; vol. 340; Dec. 12, 1992; pp. 1447-1452.
Badgett; Diagnosing the Irritable Bowel Syndrome; Annals of Internal Medicine; vol. 117, No. 12; Dec. 15, 1992; pp. 1056-1057.
Monk et al., Bezafibrate, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidamia; Drugs, Vo. 33 (6), Jun. 1987; pp. 539-576 (MEDLINE Abstract).
Drug Digest, Fibric Acid Derivatives; http://drugdigest.com/DD/PrintablePages/Comparisons/1,20038,35-15,00.html; Updated Aug. 2004.
WebMD Health; Clofibrate; http://my.webmed.com/content/drugs/1/4046—1219?bn=Atromid%2ds, (as printed on Jun. 2, 2003).
HealthSquare; Lopid; http://www.healthsquare.com
ewrx/lop1234.htm; last revised Mar. 18, 2003 (as printed on Jun. 2, 2003).
Athyros, Vasilios G., M.D., et al., “Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes with Combined Hyperlipidemia”, Diabetes Care, vol. 25, No. 7, 1198-1202 (Jul. 2002).
Mayer, Emeran A., M.D., “Irritable Bowel Syndrome”, N. Engl. J. Med., 358, 16, 1692-1699 (Apr. 17, 2008).
Hoffman & Baron LLP
Snowden Pharmaceuticals, LLC
Spivack Phyllis G.
LandOfFree
Method of treatment for irritable bowel syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for irritable bowel syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for irritable bowel syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085055